Oncolytic virotherapy as a novel strategy for pancreatic cancer

Area of Science:

• Oncology
• Gene Therapy
• Virology

Background:

• Pancreatic cancer often involves genetic alterations in TP53 and RB pathways.
• Developing targeted therapies for pancreatic cancer remains a significant challenge.
• Oncolytic viruses offer a potential strategy for cancer treatment.

Purpose of the Study:

• To develop and evaluate novel replication-selective adenoviruses for pancreatic cancer gene therapy.
• To assess the efficacy of adenoviruses targeting TP53-deficient and RB-pathway-abnormal cancer cells.
• To investigate the potential of engineered adenoviruses as therapeutic vectors and in combination with chemotherapy.

Main Methods:

• Developed E1B-55kDa-deleted adenovirus (AxE1AdB) for selective replication in TP53-deficient cells.
• Evaluated AxE1AdB in combination with uracil phosphoribosyl transferase (UPRT) to overcome 5-FU resistance.
• Constructed a double-mutant adenovirus (AxdAdB-3) targeting both TP53 and RB pathways.
• Assessed antitumor effects in vitro and in vivo using mouse models.

Main Results:

• AxE1AdB selectively replicated in and inhibited growth of human pancreatic tumors in mice.
• AxE1AdB-UPRT combined with 5-FU significantly reduced tumor burden without toxicity.
• AxE1AdB inhibited tumor angiogenesis by manipulating the E1A-pRB interaction.
• AxdAdB-3 demonstrated potent in vitro and in vivo antitumor activity.

Conclusions:

• Replication-selective adenoviruses targeting TP53 and RB pathways show significant therapeutic potential for pancreatic cancer.
• Engineered adenoviruses can serve as effective gene therapy vectors and enhance chemotherapy efficacy.
• Further development of these adenoviral strategies holds promise for treating pancreatic cancer with complex genetic abnormalities.